Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | NNMT | P40261 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2393239 | 0.76 | CDK2 (0.41) | SIRT6MKNK1MKNK2MAP4K4 | |
| SCHEMBL9763408 | 0.71 | CYP1A2 (0.43) | SIRT6NNMTPOLBALDH1A1KDM4E | |
| SCHEMBL2217788 | 0.70 | SIRT6 (0.55) | SIRT6NNMTPOLBMKNK1MKNK2 | |
| SCHEMBL1082935 | 0.70 | SIRT6 (0.42) | SIRT6NNMTPOLBMKNK1MKNK2 | |
| SCHEMBL2397345 | 0.68 | NNMT (0.54) | SIRT6NNMTMKNK1MKNK2ALDH1A1 | |
| SCHEMBL14742483 | 0.68 | PARP10 (0.41) | NNMTALDH1A1KDM4EMAP4K4 | |
| SCHEMBL3063023 | 0.67 | CYP11B2 (0.41) | SIRT6POLBALDH1A1KDM4ECYP11B1 | |
| SCHEMBL1889093 | 0.67 | ADORA3 (0.47) | SIRT6POLBKDM4E | |
| SCHEMBL27858686 | 0.66 | SIRT6 (0.40) | SIRT6NNMTPOLBALDH1A1KDM4E | |
| SCHEMBL28443920 | 0.66 | SIRT6 (0.38) | SIRT6NNMTPOLBMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017608-B2 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2011-09-13 | — | — | US | disclosed |
| EP-1608647-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-7109202-B2 | Aminothaizoles and their use as adenosine receptor antagonists | NOVARTIS AG (CH) | 2006-09-19 | — | — | US | disclosed |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2006-07-06 | — | — | US | disclosed |
| EP-1608647-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | Novartis AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| EP-1339711-B1 | AMINOTHIAZOLES AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004078754-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2004-09-16 | — | — | WO | disclosed |
| US-20040053982-A1 | Aminothaizoles and their use as adenosine receptor antagonists | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
| EP-1339711-A1 | AMINOTHIAZOLES AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042298-A1 | AMINOTHIAZOLES AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053982-A1 | Aminothaizoles and their use as adenosine receptor antagonists | ADORA1, ADORA3, HCAR1 | SIRT6 3199/4885NNMT 2681/4885POLB 3598/4885 |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | MAP3K13, AKT3, MAP3K3 | SIRT6 2987/4885NNMT 1536/4885POLB 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.